NGM - Ngm Biopharmaceuticals Inc
Close
1.54
-0.020 -1.299%
Share volume: 0
Last Updated: Thu 04 Apr 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$1.56
-0.02
-1.28%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
| Report Date | 2022-05-05 | 2022-08-04 | 2022-11-03 | 2023-02-28 | 2023-05-04 | 2023-08-03 | 2023-11-02 | |
| Assets | ||||||||
| Total Assets | 359.773 M | 337.371 M | 335.866 M | 307.402 M | 258.837 M | 220.544 M | 192.150 M | |
| Current Assets | 337.622 M | 318.839 M | 315.700 M | 288.859 M | 242.529 M | 204.402 M | 177.038 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 7.687 M | 14.357 M | 11.170 M | 9.787 M | 8.769 M | 8.623 M | 7.994 M | |
| Short Term Investments | 7.687 M | 14.357 M | 11.170 M | 9.787 M | 8.769 M | 8.623 M | 7.994 M | |
| Total Receivables | 103.000 K | 6.674 M | 4.380 M | 7.580 M | 1.257 M | 736.000 K | 0.000 | |
| Current Cash | 329.832 M | 297.808 M | 300.150 M | 271.492 M | 231.004 M | 193.544 M | 166.045 M | |
| Total Non-current Assets | 22.151 M | 18.532 M | 20.166 M | 18.543 M | 16.308 M | 16.142 M | 15.112 M | |
| Property Plant Equipment | 9.436 M | 8.480 M | 8.320 M | 8.496 M | 7.966 M | 7.760 M | 7.281 M | |
| Other Assets | 11.216 M | 8.553 M | 7.892 M | 6.093 M | 5.887 M | 5.927 M | 5.376 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 359.773 M | 337.371 M | 335.866 M | 307.402 M | 258.837 M | 220.544 M | 192.150 M | |
| Total liabilities | 48.636 M | 45.290 M | 49.977 M | 47.842 M | 37.903 M | 28.423 M | 22.345 M | |
| Total current liabilities | 44.563 M | 42.539 M | 48.596 M | 47.842 M | 37.903 M | 28.423 M | 22.345 M | |
| Accounts Payable | 4.815 M | 6.873 M | 3.565 M | 8.453 M | 13.293 M | 5.855 M | 4.690 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 5.153 M | 5.229 M | 5.307 M | 5.385 M | 4.073 M | 2.751 M | 1.381 M | |
| Long term debt | 4.073 M | 2.751 M | 1.381 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 311.137 M | 292.081 M | 285.889 M | 259.560 M | 220.934 M | 192.121 M | 169.805 M | |
| Common stock | 78.023 M | 79.270 M | 80.623 M | 81.884 M | 82.008 M | 82.456 M | 82.707 M | |
| Retained earnings | -451.416 M | -497.935 M | -545.196 M | -581.633 M | -629.280 M | -667.541 M | -696.338 M |